On Thursday, Roivant Sciences earned a positive adjustment to its Relative Strength (RS) Rating, from 69 to 73.
Can You Really Time The Stock Market?
IBD's proprietary RS Rating tracks technical performance by showing how a stock's price action over the last 52 weeks compares to that of the other stocks in our database.
History shows that the best stocks tend to have an RS Rating of at least 80 as they launch their biggest runs. See if Roivant Sciences can continue to show renewed price strength and hit that benchmark.
Roivant Sciences is working on a consolidation with a 13.05 entry. See if it can clear the breakout price in heavy trading.
The company showed 0% earnings growth in its most recent report. Revenue gains came in at -42%.
The company holds the No. 132 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Halozyme Therapeutics and Catalyst Pharmaceuticals are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
